Kempner Capital Management Inc. Purchases New Stake in Eli Lilly and Company $LLY

Kempner Capital Management Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,520 shares of the company’s stock, valued at approximately $1,923,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Willner & Heller LLC raised its holdings in shares of Eli Lilly and Company by 5.9% during the third quarter. Willner & Heller LLC now owns 936 shares of the company’s stock worth $714,000 after purchasing an additional 52 shares during the period. AMI Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $227,000. Griffin Asset Management Inc. raised its stake in Eli Lilly and Company by 47.9% during the third quarter. Griffin Asset Management Inc. now owns 784 shares of the company’s stock worth $598,000 after acquiring an additional 254 shares during the period. LeConte Wealth Management LLC lifted its holdings in Eli Lilly and Company by 50.8% in the third quarter. LeConte Wealth Management LLC now owns 864 shares of the company’s stock worth $659,000 after acquiring an additional 291 shares during the last quarter. Finally, Howard Capital Management Group LLC boosted its stake in Eli Lilly and Company by 24.3% in the third quarter. Howard Capital Management Group LLC now owns 768 shares of the company’s stock valued at $586,000 after acquiring an additional 150 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Wolfe Research increased their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research report on Monday, November 10th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Trading Up 0.0%

NYSE:LLY opened at $1,077.26 on Monday. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.70, a PEG ratio of 1.09 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The business has a fifty day moving average of $986.75 and a 200-day moving average of $841.60.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.